Bioxcel Therapeutics Inc recorded a cumulative net loss of $-71 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 380 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 4086, from total ranking in previous quarter at 4710.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BTAI Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-2,443,448	-2,597,724	-2,410,241	-2,352,103	-1,756,897
BTAI's Total Ranking	# 4086	# 4710	# 4243	# 4230	# 4167
Seq. Net Income Change	-	-	-	-	-

BTAI Company Profile >> Back to BTAI Efficiency Comparisons >> Compare BTAI Net Income per Employee to its Competitors

BTAI Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 381
Healthcare Sector	# 828
Overall Market	# 4086

Net Income per Employee Statistics
High	Average	Low
$ -664,483	$ -3,188,366	$ -7,296,793
(Dec 31 2018)		(Sep 30 2023)

News about Bioxcel Therapeutics Inc Income per employee

BioXcel Therapeutics Grapples with Roadblocks as Plans for Public Offering are Scrapped

In a recent press release, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a pioneering biopharmaceutical company specializing in neuroscience and immuno-oncology, shocked the industry by announcing the termination of its proposed public offering. This decision comes in the wake of significant financial setbacks, including a cumulative net loss of $212 million in the third quarter of 2023. Additionally, the company s ranking has seen a decline from 2568 to 2942 compared to the previous quarter.
1. BioXcel s Decision to Terminate the Public Offering:
On February 8, 2024, BioXcel Therapeutics had announced its plan to raise $60.0 million through a public offering of its common stock, or alternatively through pre-funded warrants. However, the company has abruptly decided to cancel this offering, meaning no securities of the company will be sold as initially planned. This unexpected move raises questions about BioXcel s financial stability and future prospects.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-03T11:36:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.